Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 01, 2015 8:39 PM ET


Company Overview of Protein Sciences Corporation

Company Overview

Protein Sciences Corporation develops, manufactures, and commercializes vaccines and biopharmaceuticals for the prevention and treatment of various diseases. The company offers Flublok, a recombinant protein-based seasonal influenza vaccine; Panblok, a pandemic influenza vaccine; FluNhance that is used to enhance additive to influenza vaccines; and SARS (D3252), a Severe Acute Respiratory Syndrome vaccine that is used to elicit neutralizing antibodies to the virus. It also provides Baculovirus Expression Vector System, a platform technology used for the development of a range of vaccines and therapeutics, such as prophylactic vaccines, therapeutic vaccines, gene therapy, and biologic applica...

1000 Research Parkway

Meriden, CT 06450

United States

Founded in 1983





Key Executives for Protein Sciences Corporation

Chief Executive Officer, President and Director
Chief Administrative Officer, Senior Vice President and Corporate Secretary
Chief Medical Officer
Head of Government and Clinical Affairs
Executive Chairman and Global Head of Business Development
Age: 74
Compensation as of Fiscal Year 2015.

Protein Sciences Corporation Key Developments

Protein Sciences New York Facility Receives FDA Licensure to Manufacture Flublok®

Protein Sciences Corporation announced that on May 12, 2015 the U.S. Food and Drug Administration (FDA) licensed its Pearl River, NY manufacturing facility for the commercial manufacturing of Flublok® influenza vaccine. Flublok is the world's first licensed influenza vaccine made using modern recombinant technology. The approval of its Pearl River facility accelerates the growth of Protein Sciences and Flublok.

Protein Sciences Corporation, UMN Pharma Inc. and IHI Corporation Enter into Agreement to Evaluate Sourcing Flublok® from Japan

Protein Sciences Corporation, UMN Pharma Inc. and IHI Corporation announced that they have entered into an agreement to assess the feasibility of sourcing the active ingredients of Flublok influenza vaccine from Japan. The drug substances would be manufactured at the Gifu (Japan) Plant of UNIGEN, a subsidiary of UMN Pharma in which IHI holds 50% of the common shares. UNIGEN manufactures Flublok for UMN Pharma at the 21,000L scale - ten times the scale the vaccine is manufactured in the United States. The Gifu plant has two 21,000L bioreactors and has the capacity to add six additional bioreactors. UMN holds a license from Protein Sciences for Flublok for the territories of Japan, China, Korea, Hong Kong, Taiwan and Singapore. UMN is partnered with Astellas to market Flublok in Japan.

Protein Sciences Corporation Presents at 12th Annual BIO Asia International Conference, Mar-25-2015 01:00 PM

Protein Sciences Corporation Presents at 12th Annual BIO Asia International Conference, Mar-25-2015 01:00 PM. Venue: Grand Hyatt Hotel, Tokyo, Japan.

Similar Private Companies By Industry

Company Name Region
Celtaxsys, Inc. United States
Atlas U.S. Royalty, LLC United States
Shimoda Atlantic, Inc. United States
Remington Health Products, LLC United States
Anodyne Dental Pharma Inc. United States

Recent Private Companies Transactions

December 18, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Protein Sciences Corporation, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at